Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Mechanism of action of KCNQ openers: an emerging class of anti-epileptic drugs
EF 2017-18
Résumé
Epilepsy is a common and debilitating neurological condition involving excessive neuronal activity that leads to seizures. Although many drugs are available, a significant proportion (~30%) of epilepsy patients are unresponsive to existing therapeutics. The main reason for this gap in treatment is that many antiepileptics have redundant mechanisms (overlapping molecular targets), and so an important approach has been the development of drugs with new mechanisms. Retigabine is the first antiepileptic that acts by opening voltage-gated potassium (Kv) channels. Although this drug has not been a commercial success, it has proven effective in clinical trials, and a useful alternative for subgroups of patients with drug-resistant epilepsy.
Although therapeutic effects of Retigabine have been demonstrated, the understanding of its mechanism lags far behind more established classes of anticonvulsants. The purpose of my proposed research is to investigate in detail the mechanism of action of retigabine on its molecular target: neuronal ‘M-channels’ encoded by the KCNQ gene family. Retigabine promotes M-channel opening via a complex mechanism involving interaction with the channel and an associated phospholipid (PIP2). This project will identify determinants of interactions between the channel, PIP2, and retigabine (and recently developed analogs), in order to define the molecular basis of action and guide the development of improved KCNQ activators.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386663
Name
Li Jingru
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mechanism of action of KCNQ openers: an emerging class of anti-epileptic drugs
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Conductance; Convulsion; Electrophysiology; Epilepsy; Fluorescence; Ion Channel; Mutagenesis; Neuron; Potassium; Retigabine
Abstract
Epilepsy is a common and debilitating neurological condition involving excessive neuronal activity that leads to seizures. Although many drugs are available, a significant proportion (~30%) of epilepsy patients are unresponsive to existing therapeutics. The main reason for this gap in treatment is that many antiepileptics have redundant mechanisms (overlapping molecular targets), and so an important approach has been the development of drugs with new mechanisms. Retigabine is the first antiepileptic that acts by opening voltage-gated potassium (Kv) channels. Although this drug has not been a commercial success, it has proven effective in clinical trials, and a useful alternative for subgroups of patients with drug-resistant epilepsy.
Although therapeutic effects of Retigabine have been demonstrated, the understanding of its mechanism lags far behind more established classes of anticonvulsants. The purpose of my proposed research is to investigate in detail the mechanism of action of retigabine on its molecular target: neuronal ‘M-channels’ encoded by the KCNQ gene family. Retigabine promotes M-channel opening via a complex mechanism involving interaction with the channel and an associated phospholipid (PIP2). This project will identify determinants of interactions between the channel, PIP2, and retigabine (and recently developed analogs), in order to define the molecular basis of action and guide the development of improved KCNQ activators.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Jingru
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~